Targeted delivery of doxorubicin using a colorectal cancer-specific ssDNA aptamer

Anatomical Record

Volumn 297, Issue 12, 2014, Pages 2280-2288

  Li, Wanming ^a   Chen, Hang ^a   Yu, Min ^a   Fang, Jin ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Aptamer; Colorectal cancer; Doxorubicin; Drug delivery; Targeted therapy

Indexed keywords

APTAMER; DOXORUBICIN; L33 APTAMER; SINGLE STRANDED DNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; DRUG CARRIER;

ARTICLE; BINDING AFFINITY; CELL VIABILITY; COLORECTAL CANCER; CYTOTOXICITY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; FEASIBILITY STUDY; HCT116 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IC50; INTERNALIZATION; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; TARGET CELL; APOPTOSIS; CELL PROLIFERATION; CHEMISTRY; COLORECTAL NEOPLASMS; DRUG EFFECTS; FLOW CYTOMETRY; PATHOLOGY; TUMOR CELL CULTURE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; APTAMERS, NUCLEOTIDE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DNA, SINGLE-STRANDED; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; HUMANS; TUMOR CELLS, CULTURED;

EID: 84917732353     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.22990     Document Type: Article

References (37)

1. Alberts DS, Delforge A. 2006. Maximizing the delivery of intraperitoneal therapy while minimizing drug toxicity and maintaining quality of life. Semin Oncol 33:S8-17.
2. Bagalkot V, Farokhzad OC, Langer R, Jon S. 2006. An aptamer-doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Int Ed Engl 45:8149-8152.
3. Cao X, Li S, Chen L, Ding H, Xu H, Huang Y, Li J, Liu N, Cao W, Zhu Y, Shen B, Shao N. 2009. Combining use of a panel of ssDNA aptamers in the detection of Staphylococcus aureus. Nucleic Acids Res 37:4621-4628.
4. Chen CH, Dellamaggiore KR, Ouellette CP, Sedano CD, Lizadjohry M, Chernis GA, Gonzales M, Baltasar FE, Fan AL, Myerowitz R, Neufeld EF. 2008. Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl Acad Sci USA 105:15908-15913.
5. Corte H, Manceau G, Blons H, Laurent-Puig P. 2012. MicroRNA and colorectal cancer. Dig Liver Dis 44:195-200.
6. Daneker GW, Jr., Piazza AJ, Steele GD, Jr., Mercurio AM. 1989. Relationship between extracellular matrix interactions and degree of differentiation in human colon carcinoma cell lines. Cancer Res 49:681-686.
7. Dhar S, Kolishetti N, Lippard SJ, Farokhzad OC. 2011. Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. Proc Natl Acad Sci USA 108:1850-1855.
8. Ding D, Allman BL, Salvi R. 2012. Review: ototoxic characteristics of platinum antitumor drugs. Anat Rec (Hoboken) 295:1851-1867.
9. Ellington AD, Szostak JW. 1990. In vitro selection of RNA molecules that bind specific ligands. Nature 346:818-822.
10. Fang X, Tan W. 2010. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res 43:48-57.
11. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, Richie JP, Langer R. 2006. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103:6315-6320.
12. Gao H, Qian J, Yang Z, Pang Z, Xi Z, Cao S, Wang Y, Pan S, Zhang S, Wang W, Jiang X, Zhang Q. 2012. Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(epsilon-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials 33:6264-6272.
13. Hu Y, Duan J, Zhan Q, Wang F, Lu X, Yang XD. 2012. Novel MUC1 aptamer selectively delivers cytotoxic agent to cancer cells in vitro. PLoS One 7:e31970.
14. Huang YF, Shangguan D, Liu H, Phillips JA, Zhang X, Chen Y, Tan W. 2009. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. Chembiochem 10:862-868.
15. Jemal A, Center MM, DeSantis C, Ward EM. 2010. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19:1893-1907.
16. Lai WY, Wang WY, Chang YC, Chang CJ, Yang PC, Peck K. 2014. Synergistic inhibition of lung cancer cell invasion, tumor growth and angiogenesis using aptamer-siRNA chimeras. Biomaterials 35:2905-2914.
17. Li DC, Zhong XK, Zeng ZP, Jiang JG, Li L, Zhao MM, Yang XQ, Chen J, Zhang BS, Zhao QZ, Xie MY, Xiong H, Deng ZY, Zhang XM, Xu SY, Gao YX. 2009a. Application of targeted drug delivery system in Chinese medicine. J Control Release Soc 138:103-112.
18. Li N, Ebright JN, Stovall GM, Chen X, Nguyen HH, Singh A, Syrett A, Ellington AD. 2009b. Technical and biological issues relevant to cell typing with aptamers. J Proteome Res 8:2438-2448.
19. Li X, Zhao Q, Qiu L. 2013. Smart ligand: aptamer-mediated targeted delivery of chemotherapeutic drugs and siRNA for cancer therapy. J Control Release 171:152-162.
20. Liao W, Liao Y, Zhou JX, Xie J, Chen J, Huang W, Luo R. 2010. Gene mutations in epidermal growth factor receptor signaling network and their association with survival in Chinese patients with metastatic colorectal cancers. Anat Rec (Hoboken) 293:1506-1511.
21. Liu X, Chen L, Feng B, Liu G. 2014. Reversing effect of sorcin in the drug resistance of human nasopharyngeal carcinoma. Anat Rec (Hoboken) 297:215-221.
22. Liu Z, Duan JH, Song YM, Ma J, Wang FD, Lu X, Yang XD. 2012. Novel HER2 aptamer selectively delivers cytotoxic drug to HER2-positive breast cancer cells in vitro. J Transl Med 10:148.
23. Meng L, Yang L, Zhao X, Zhang L, Zhu H, Liu C, Tan W. 2012. Targeted delivery of chemotherapy agents using a liver cancer-specific aptamer. PLoS One 7:e33434.
24. Minko T, Rodriguez-Rodriguez L, Pozharov V. 2013. Nanotechnology approaches for personalized treatment of multidrug resistant cancers. Adv Drug Deliv Rev 65:1880-1895.
25. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. 2004. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56:185-229.
26. Sefah K, Shangguan D, Xiong X, O'Donoghue MB, Tan W. 2010. Development of DNA aptamers using Cell-SELEX. Nat Protocol 5:1169-1185.
27. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, Sefah K, Yang CJ, Tan W. 2006. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 103:11838-11843.
28. Shapira A, Livney YD, Broxterman HJ, Assaraf YG. 2011. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updates 14:150-163.
29. Siegel R, Naishadham D, Jemal A. 2013. Cancer statistics, 2013. CA Cancer J Clin 63:11-30.
30. Tuerk C, Gold L. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510.
31. Wang CH, Kang ST, Lee YH, Luo YL, Huang YF, Yeh CK. 2012. Aptamer-conjugated and drug-loaded acoustic droplets for ultrasound theranosis. Biomaterials 33:1939-1947.
32. Yang JL, Hanley JR, Yu Y, Berney CR, Russell PJ, Crowe PJ. 1997. In vivo overexpression of c-erbB-2 oncoprotein in xenografts of mice implanted with human colon cancer lines. Anticancer Res 17:3463-3468.
33. Ye M, Hu J, Peng M, Liu J, Liu J, Liu H, Zhao X, Tan W. 2012. Generating aptamers by cell-SELEX for applications in molecular medicine. Int J Mol Sci 13:3341-3353.
34. Zhang L, Radovic-Moreno AF, Alexis F, Gu FX, Basto PA, Bagalkot V, Jon S, Langer RS, Farokhzad OC. 2007. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2:1268-1271.
35. Zhang Y, Hong H, Cai W. 2011. Tumor-targeted drug delivery with aptamers. Curr Med Chem 18:4185-4194.
36. Zhao N, You J, Zeng Z, Li C, Zu Y. 2013. An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells. Small 9:3477-3484.
37. Zhu G, Zheng J, Song E, Donovan M, Zhang K, Liu C, Tan W. 2013. Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc Natl Acad Sci USA 110:7998-8003.